325 related articles for article (PubMed ID: 26206420)
1. An overview of early investigational therapies for chemoresistant ovarian cancer.
Marchetti C; Ledermann JA; Benedetti Panici P
Expert Opin Investig Drugs; 2015; 24(9):1163-83. PubMed ID: 26206420
[TBL] [Abstract][Full Text] [Related]
2. An overview of tyrosine kinase inhibitors for the treatment of epithelial ovarian cancer.
Wang Z; Fu S
Expert Opin Investig Drugs; 2016; 25(1):15-30. PubMed ID: 26560712
[TBL] [Abstract][Full Text] [Related]
3. The safety of antiangiogenic agents and PARP inhibitors in platinum-sensitive recurrent ovarian cancer.
Lorusso D; Fontanella C; Maltese G; Lepori S; Tripodi E; Bogani G; Raspagliesi F
Expert Opin Drug Saf; 2017 Jun; 16(6):687-696. PubMed ID: 28471247
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of trebananib (AMG 386) in treating epithelial ovarian cancer.
Al Wadi K; Ghatage P
Expert Opin Pharmacother; 2016; 17(6):853-60. PubMed ID: 26933765
[TBL] [Abstract][Full Text] [Related]
5. Emerging growth factor receptor antagonists for ovarian cancer treatment.
Bonilla L; Oza A; Lheureux S
Expert Opin Emerg Drugs; 2018 Mar; 23(1):1-16. PubMed ID: 29528256
[TBL] [Abstract][Full Text] [Related]
6. Investigational therapies currently in Phase II clinical trials for the treatment of pelvic serous carcinomas.
Bergamini A; Leone Roberti Maggiore U; Ferrero S; Rabaiotti E; Viganò R; Petrone M; De Marzi P; Salvatore S; Candiani M; Mangili G
Expert Opin Investig Drugs; 2015 Mar; 24(3):345-62. PubMed ID: 25640877
[TBL] [Abstract][Full Text] [Related]
7. Current and emerging treatment options in the management of advanced ovarian cancer.
Rodriguez-Freixinos V; Mackay HJ; Karakasis K; Oza AM
Expert Opin Pharmacother; 2016 Jun; 17(8):1063-76. PubMed ID: 26918413
[TBL] [Abstract][Full Text] [Related]
8. An update on current and emerging therapies for epithelial ovarian cancer: Focus on poly(adenosine diphosphate-ribose) polymerase inhibition and antiangiogenesis.
Chung C; Lee R
J Oncol Pharm Pract; 2017 Sep; 23(6):454-469. PubMed ID: 27357817
[TBL] [Abstract][Full Text] [Related]
9. Maintenance therapy in epithelial ovarian cancer: from chemotherapy to targeted agents.
Falci C; Dieci MV; Guarneri V; Soldà C; Bria E; Tortora G; Conte P
Expert Rev Anticancer Ther; 2014 Sep; 14(9):1041-50. PubMed ID: 24953376
[TBL] [Abstract][Full Text] [Related]
10. Advances in the treatment of platinum resistant epithelial ovarian cancer: an update on standard and experimental therapies.
Leung SOA; Konstantinopoulos PA
Expert Opin Investig Drugs; 2021 Jul; 30(7):695-707. PubMed ID: 34082614
[No Abstract] [Full Text] [Related]
11. Optimizing treatment in recurrent epithelial ovarian cancer.
Corrado G; Salutari V; Palluzzi E; Distefano MG; Scambia G; Ferrandina G
Expert Rev Anticancer Ther; 2017 Dec; 17(12):1147-1158. PubMed ID: 29086618
[TBL] [Abstract][Full Text] [Related]
12. Chemotherapy for Patients with BRCA1 and BRCA2-Mutated Ovarian Cancer: Same or Different?
Tan DS; Kaye SB
Am Soc Clin Oncol Educ Book; 2015; ():114-21. PubMed ID: 25993149
[TBL] [Abstract][Full Text] [Related]
13. Recurrent epithelial ovarian cancer: pharmacotherapy and novel therapeutics.
Modesitt SC; Jazaeri AA
Expert Opin Pharmacother; 2007 Oct; 8(14):2293-305. PubMed ID: 17927484
[TBL] [Abstract][Full Text] [Related]
14. Defining and targeting wild-type BRCA high-grade serous ovarian cancer: DNA repair and cell cycle checkpoints.
Ivy SP; Kunos CA; Arnaldez FI; Kohn EC
Expert Opin Investig Drugs; 2019 Sep; 28(9):771-785. PubMed ID: 31449760
[No Abstract] [Full Text] [Related]
15. A brief review of the management of platinum-resistant-platinum-refractory ovarian cancer.
Oronsky B; Ray CM; Spira AI; Trepel JB; Carter CA; Cottrill HM
Med Oncol; 2017 Jun; 34(6):103. PubMed ID: 28444622
[TBL] [Abstract][Full Text] [Related]
16. Pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant, recurrent, pre-treated ovarian cancer - Results of the PACOVAR-trial.
Dinkic C; Eichbaum M; Schmidt M; Grischke EM; Gebauer G; Fricke HC; Lenz F; Wallwiener M; Marme F; Schneeweiss A; Sohn C; Rom J
Gynecol Oncol; 2017 Aug; 146(2):279-284. PubMed ID: 28528917
[TBL] [Abstract][Full Text] [Related]
17. Predicting platinum resistance in primary advanced ovarian cancer patients with an in vitro resistance index.
Hetland TE; Kærn J; Skrede M; Sandstad B; Tropé C; Davidson B; Flørenes VA
Cancer Chemother Pharmacol; 2012 May; 69(5):1307-14. PubMed ID: 22302409
[TBL] [Abstract][Full Text] [Related]
18. Response rates to second-line platinum-based therapy in ovarian cancer patients challenge the clinical definition of platinum resistance.
Lindemann K; Gao B; Mapagu C; Fereday S; Emmanuel C; Alsop K; Traficante N; ; Harnett PR; Bowtell DDL; deFazio A
Gynecol Oncol; 2018 Aug; 150(2):239-246. PubMed ID: 29807697
[TBL] [Abstract][Full Text] [Related]
19. Targeting genetic and epigenetic alterations in the treatment of serous ovarian cancer.
Weberpals JI; Koti M; Squire JA
Cancer Genet; 2011 Oct; 204(10):525-35. PubMed ID: 22137482
[TBL] [Abstract][Full Text] [Related]
20. Critical role of Wnt/β-catenin signaling in driving epithelial ovarian cancer platinum resistance.
Nagaraj AB; Joseph P; Kovalenko O; Singh S; Armstrong A; Redline R; Resnick K; Zanotti K; Waggoner S; DiFeo A
Oncotarget; 2015 Sep; 6(27):23720-34. PubMed ID: 26125441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
